April 26th 2025
A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the originator in a pooled analysis of the VOLTAIRE clinical trials.
Samsung Bioepis Report Proves Lower Biosimilar Prices Correlate With Greater Market Share
July 19th 2023The second edition of Samsung Bioepis’ Biosimilar Market Report shows strong correlation between biosimilar usage and decreased drug prices, proving that biosimilars are delivering on the promise of savings and price erosion.
Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price
July 17th 2023The list price of Humira (reference adalimumab) has risen so dramatically over time that the list prices for new adalimumab biosimilars are now significantly higher than the original price of the originator, according to a report contextualizing net prices of adalimumab and the role of rebates.
Will the Entry of Adalimumab Biosimilars to the US Market Successfully Lower Spending?
July 15th 2023A review article sheds light on the growing adalimumab market in the US, including how these products are being priced, strategies companies are using to make their product stand out, and recommendations for policymakers to ensure the accessibility and affordability of these products.
The Age of Adalimumab Is Upon Us: How Stakeholders Can Prepare
June 28th 2023The Center for Biosimilars® provides an updated look on the adalimumab biosimilars that are coming down the US pipeline as well as what stakeholders need to know and how they can prepare ahead of the US launch of 8 adalimumab biosimilars in July 2023.
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
June 1st 2023The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.
Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
May 14th 2023In light of 2 blockbuster originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity in 2023, 3 doctors penned supplement in The American Journal of Managed Care®. On this episode, Vibeke Strand, MD, one of the co-authors, explored how health systems can take charge and boost biosimilar adoption.
Julie Reed: The Status Quo for Biosimilars Needs to Change to Maintain the Industry
May 11th 2023The 2023 Asembia Specialty Pharmacy Summit featured Juliana (Julie) Reed, executive director of the Biosimilars Forum, who spoke on the challenges still facing the biosimilars industry and how they may impact the success of adalimumab biosimilars in the United States.
Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption
May 10th 2023In the first edition of Samsung Bioepis’ Biosimilar Market Report, the company outlined the current state of the US biosimilars market and how increasing adoption has had an impact on pricing changes for biosimilars and their reference products.
FDA Issues Another CRL for Alvotech’s Adalimumab Biosimilar
April 14th 2023In a complete response letter (CRL) for Alvotech, the FDA cited “deficiencies” in the company’s manufacturing facility during a reinspection, further delaying the approval for the ninth adalimumab biosimilar until potentially June 2023.
Spherix Global Insights: Despite High Awareness, Provider Comfort With Adalimumab Biosimilars Is Low
April 3rd 2023Although rheumatologists, dermatologists, and gastroenterologists rated their awareness of adalimumab biosimilars as high, a significant proportion of each group reported that they were not confident prescribing a biosimilar over the originator.
Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy
March 30th 2023Yukon, 1 of 3 Canadian territories, announced that it will implement a biosimilars switching policy, following Newfoundland and Labrador’s announcement to move forward with a similar policy earlier this week.
Favorable Equivalency Studies of Candidate Biosimilar AVT04 and Reference Ustekinumab
March 27th 2023Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).
Retrospective Study Supports Safety of Anti-TNF Biosimilars During Pregnancy
March 18th 2023More and more women are becoming pregnant while on anti–tumor necrosis factor (TNF) biosimilars used to treat inflammatory disorders. However, there is “little data” on the safety and effectiveness of biosimilars in pregnancy, according to authors of a recent retrospective study.
CVS Predicts Interchangeability Won’t Drive Adalimumab Biosimilar Adoption
March 15th 2023In a report from CVS Health, interchangeability will not be a primary factor in driving the adoption of adalimumab biosimilars referencing Humira, contradicting predictions from other sources that believe the designation will impact prescribing habits.
Eye on Pharma: FDA, EMA Accept Biosimilar Applications; Biosimilar Trials Begin
March 9th 2023The FDA and the European Medicines Agency (EMA) accepted applications for a trastuzumab biosimilar and an ustekinumab biosimilar, respectively, and Altos Biologics completed patient enrollment for a phase 3 trial assessing an aflibercept biosimilar.
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
February 23rd 2023In Cardinal Health’s 2023 Biosimilars Report, more than 60% of surveyed providers said they would only want to prescribe adalimumab biosimilars with interchangeability designations, suggesting the label may have a greater impact on uptake than originally expected.
Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?
January 7th 2023The authors of an retrospective real-world study of patients with hidradenitis suppurativa treated with adalimumab concluded that switching patients between adalimumab products risked a greater likelihood of loss of effectiveness.